SAN FRANCISCO, Oct. 3, 2018 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing innovative gene therapy
products for patients living with serious, life-threatening rare
diseases, today announced that Co-Founder and Chief Executive
Officer (CEO) Matthew R. Patterson
has been appointed Chairman of the Alliance for Regenerative
Medicine (ARM), the international advocacy organization
representing the gene and cell therapy and broader regenerative
medicine sector. Mr. Patterson has served as Vice Chairman of
ARM since August 2016.
"Today's announcement is the natural progression of the
important contributions that Matt has made through multiple
leadership roles at the Alliance for Regenerative Medicine," stated
Janet Lynch Lambert, CEO of
ARM. "Matt brings significant expertise in the development of
novel therapies for rare genetic disorders that address serious,
life-threatening rare diseases, and his deep entrepreneurial
experience and track record of success are valued by the ARM
leadership team."
Prior to his role as Vice Chairman, Mr. Patterson was a member
of the board of directors at ARM. In his various leadership
positions, Mr. Patterson has been responsible for the support and
promotion of ARM's global strategy to increase funding for the
research and development of advanced gene and cell-based therapies,
as well as addressing industry issues around regulatory science and
reimbursement to support marketing approval and commercial
acceptance of safe and effective regenerative medicine
products.
"The Alliance for Regenerative Medicine advocates for progress
in gene therapy, cell therapy, and tissue engineering, and I am
deeply committed to this mission," said Mr. Patterson. "ARM
provides a critical forum to ensure the successful development and
future availability of innovative new treatments for patients, and
I welcome the opportunity to expand my leadership role within the
organization."
Mr. Patterson has 25 years of experience in the research,
development, and commercialization of innovative treatments for
rare diseases and has held positions of senior management in both
private and public biotechnology companies. He is the
co-founder of Audentes and has served as CEO since the Company's
inception in November 2012. Previously, Mr. Patterson worked
for Amicus Therapeutics, BioMarin Pharmaceutical, and Genzyme
Corporation. Prior to Audentes he was an
Entrepreneur-In-Residence with OrbiMed, the world's largest
health-care dedicated investment firm.
About the Alliance for Regenerative Medicine
The
Alliance for Regenerative Medicine (ARM) is an international
multi-stakeholder advocacy organization that promotes legislative,
regulatory and reimbursement initiatives necessary to facilitate
access to life-giving advances in regenerative medicine worldwide.
ARM also works to increase public understanding of the field
and its potential to transform human healthcare, providing business
development and investor outreach services to support the growth of
its member companies and research organizations. Prior to the
formation of ARM in 2009, there was no advocacy organization
operating in Washington, D.C. to
specifically represent the interests of the companies, research
institutions, investors and patient groups that comprise the entire
regenerative medicine community. Today, ARM has more than 300
members and is the leading global advocacy organization in this
field. To learn more about ARM or to become a member, visit
http://www.alliancerm.org.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused
on developing and commercializing innovative gene therapy products
for patients living with serious, life-threatening rare
diseases. We are currently conducting
Phase 1/2 clinical studies of our lead product
candidates, AT132 for the treatment of XLMTM, and AT342 for the
treatment of Crigler-Najjar syndrome. We have two additional
product candidates in development, including AT982 for the
treatment of Pompe disease, and AT307 for the treatment of the
CASQ2 subtype of catecholaminergic polymorphic ventricular
tachycardia (CASQ2-CPVT). We are a focused, experienced and
passionate team committed to forging strong, global relationships
with the patient, research and medical communities.
For more information regarding Audentes, please visit
www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-announces-co-founder-and-chief-executive-officer-matthew-r-patterson-appointed-chairman-of-the-alliance-for-regenerative-medicine-300723311.html
SOURCE Audentes Therapeutics, Inc.